Spectrum of medulloblastoma subtypes and frequency of MYC amplification; Experience from a tertiary care center in Saudi Arabia

References

1. ↵
   1. Louis DN,
   2. Perry A,
   3. Reifenberger G,
   4. von Deimling A,
   5. Figarella-Branger D,
   6. Cavenee WK,
   7. et al.

   (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131, 803–820.
2. ↵
   1. Pietsch T,
   2. Haberler C

   (2016) Update on the integrated histopathological and genetic classification of medulloblastoma - a practical diagnostic guideline. Clin Neuropathol 35, 344–352.
3. ↵
   1. Borowska A,
   2. Jóźwiak J

   (2016) Medulloblastoma: molecular pathways and histopathological classification. Arch Med Sci 12, 659–666.
4. ↵
   1. Ellison DW,
   2. Dalton J,
   3. Kocak M,
   4. Nicholson SL,
   5. Fraga C,
   6. Neale G,
   7. et al.

   (2011) Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 121, 381–396.
5. ↵
   1. Aldosari N,
   2. Bigner SH,
   3. Burger PC,
   4. Becker L,
   5. Kepner JL,
   6. Friedman HS,
   7. et al.

   (2002) MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children’s Oncology Group. Arch Pathol Lab Med 126, 540–544.
6. ↵
   1. Alharbi M,
   2. Mobark N,
   3. Bashawri Y,
   4. Abu Safieh L,
   5. Alowayn A,
   6. Aljelaify R,
   7. et al.

   (2020) Methylation profiling of medulloblastoma in a clinical setting permits sub-classification and reveals new outcome predictions. Front Neurol 11, 167.
7. ↵
   1. Gajjar A,
   2. Bowers DC,
   3. Karajannis MA,
   4. Leary S,
   5. Witt H,
   6. Gottardo NG

   (2015) Pediatric brain tumors: innovative genomic information is transforming the diagnostic and clinical landscape. J Clin Oncol 33, 2986–2998.
8. ↵
   1. Eberhart CG,
   2. Kepner JL,
   3. Goldthwaite PT,
   4. Kun LE,
   5. Duffner PK,
   6. Friedman HS,
   7. et al.

   (2002) Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 94, 552–560.
9. ↵
   1. Ellison DW,
   2. Kocak M,
   3. Dalton J,
   4. Megahed H,
   5. Lusher ME,
   6. Ryan SL,
   7. et al.

   (2011) Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 29, 1400–1407.
10. ↵
    1. Pfister S,
    2. Remke M,
    3. Benner A,
    4. Mendrzyk F,
    5. Toedt G,
    6. Felsberg J,
    7. et al.

    (2009) Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 27, 1627–1636.
11. ↵
    1. Northcott PA,
    2. Shih DJ,
    3. Peacock J,
    4. Garzia L,
    5. Morrissy AS,
    6. Zichner T,
    7. et al.

    (2012) Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 488, 49–56.
12. ↵
    1. Ryan SL,
    2. Schwalbe EC,
    3. Cole M,
    4. Lu Y,
    5. Lusher ME,
    6. Megahed H,
    7. et al.

    (2012) MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol 123, 501–513.
13. ↵
    1. Korshunov A,
    2. Remke M,
    3. Werft W,
    4. Benner A,
    5. Ryzhova M,
    6. Witt H,
    7. et al.

    (2010) Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol 28, 3054–3060.
14. ↵
    1. Northcott PA,
    2. Robinson GW,
    3. Kratz CP,
    4. Mabbott DJ,
    5. Pomeroy SL,
    6. Clifford SC,
    7. et al.

    (2019) Medulloblastoma. Nat Rev Dis Primers 5, 11.